IN8BIO INC

Company Overview

IN8bio Inc. is a clinical-stage biopharmaceutical company (Healthcare sector, Biotechnology industry) developing gamma‑delta T cell therapies and pan‑gamma‑delta T cell engagers for oncology and select autoimmune diseases. Its DeltEx platform supports multiple modalities (allogeneic, autologous, iPSC‑derived and engineered cells) with lead programs INB‑100 (post‑transplant maintenance in hematologic malignancies) and INB‑200/400 (chemotherapy‑resistant DRI gamma‑delta cells for glioblastoma), plus preclinical TCE and iPSC programs. The company is R&D‑focused, capital constrained (substantial doubt about going concern without new funding), relies on academic collaborators and third‑party GMP manufacturers, and has limited headcount and no commercial organization.

Executive Compensation Practices

As a small, research‑intensive biotech, executive pay is likely equity‑heavy and milestone‑oriented: base salaries are modest relative to larger peers, with significant reliance on stock‑based awards and performance or milestone triggers tied to clinical progress (e.g., dose‑finding, enrollment, data readouts, IND/BLA enabling activities). Filing disclosures confirm stock‑based compensation is a critical accounting judgment (Black‑Scholes inputs) and the company has recently reduced cash compensation and bonuses during cost‑savings actions (Sept 2024 workforce reduction), increasing the relative importance of equity and retention grants. Typical sector norms (Healthcare / Biotechnology) — low cash pay, long‑dated options/RSUs, severance protections for key hires, and milestone vesting — will shape packages here, and licensing milestones/royalties to Emory/UABRF may indirectly influence pay structures if cash payments are required.

Insider Trading Considerations

Insider trading activity at IN8bio will likely cluster around clinical and financing catalysts: INB‑100 expansion cohort readouts, preclinical INB‑600 presentations, and any announcements about partnerships or warrant/ATM financings are material events that can drive insider buys/sells or Rule 10b5‑1 plan activity. Given tight cash runway and frequent equity financings (private placements, ATM sales, outstanding warrants and recent warrant exercises), insiders may more often exercise warrants or sell shares to diversify or provide liquidity; conversely, open‑market buys would be a stronger signal of conviction but are less common in cash‑strained biotechs. Regulatory rules (SEC Section 16 short‑swing profit rules, company blackout periods around clinical data and filings) and clinical‑stage confidentiality mean insiders should be expected to use defined trading windows or 10b5‑1 plans; watch for concentration of transactions near financings, reverse split events (1‑for‑30 on June 5, 2025), or warrant amendments that change exercise economics.